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Abstract
Background: The APC tumour suppressor functions in several cellular processes including the regulation of b-catenin in Wnt
signalling and in cell adhesion and migration.
Findings: In this study, we establish that in epithelial cells N-terminally phosphorylated b-catenin specifically localises to
several subcellular sites including cell-cell contacts and the ends of cell protrusions. N-terminally phosphorylated b-catenin
associates with E-cadherin at adherens junctions and with APC in cell protrusions. We isolated APC-rich protrusions from
stimulated cells and detected b-catenin, GSK3b and CK1a, but not axin. The APC/phospho-b-catenin complex in cell
protrusions appears to be distinct from the APC/axin/b-catenin destruction complex. GSK3b phosphorylates the APC-
associated population of b-catenin, but not the cell junction population. b-catenin associated with APC is rapidly
phosphorylated and dephosphorylated. HGF and wound-induced cell migration promote the localised accumulation of APC
and phosphorylated b-catenin at the leading edge of migrating cells. APC siRNA and analysis of colon cancer cell lines show
that functional APC is required for localised phospho-b-catenin accumulation in cell protrusions.
Conclusions: We conclude that N-terminal phosphorylation of b-catenin does not necessarily lead to its degradation but
instead marks distinct functions, such as cell migration and/or adhesion processes. Localised regulation of APC-phospho-b-
catenin complexes may contribute to the tumour suppressor activity of APC.
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Introduction
MutationoftheAdenomatousPolyposisColi(APC)gene isresponsible
for over 80% of colon tumours, and is the first detectable event in
colorectal neoplasia [1,2]. The current paradigm for most colon
cancers is that truncation of APC disrupts the regulation of the
cellular concentration of b-catenin by proteasome-mediated
degradation [3,4]. The critical step is the phosphorylation of b-
catenin at Ser33 and Ser37, within an APC- and axin-containing
complex known as the ‘‘b-catenin destruction complex’’. Phospho-
Ser33/37-b-catenin comprise a recognition sequence for the
bTrCP E3 ligase, resulting in the ubiquitination and subsequent
degradation of b-catenin [5,6,7]. Mutations in b-catenin in a
number of tumour types can also prevent its phosphorylation [8].
The failure of the APC-axin-b-catenin destruction complex to
phosphorylate b-catenin is proposed to result in the accumulation of
b-catenin and subsequent constitutive activation of Wnt/b-catenin-
target genes,whichareimportant ingutdevelopmentandindriving
colorectal tumourigenesis [9,10,11].
Evidence is accumulating that the mechanism of regulation of
different cellular processes by b-catenin is more complex than
simply involving the control of total cellular levels of the protein
[12,13,14]. b-catenin has been proposed to be regulated by
changes in its conformation, where different molecular forms act
in adhesion or transcription, respectively [14]. b-catenin is also
regulated by E-cadherin-mediated cell-cell adhesion and tyrosine
phosphorylation [13,15]. For example, phosphorylation of b-
catenin at Tyr654 results in its dissociation from E-cadherin [16]
and phosphorylation at Tyr142 acts as a switch that disrupts its
binding to a-catenin and promotes binding of BCL9-2, a nuclear
co-factor, resulting in increased transcription of Wnt-target genes
[13].
While several studies using phospho (Ser33/37/41/45)-specific
b-catenin antibodies reinforce the concept that N-terminal
phosphorylation of b-catenin leads to its degradation [17,18],
recent work implicates N-terminally phosphorylated b-catenin in
distinct functions, including microtubule regrowth at centrosomes
[19] and Wnt5a-induced b-catenin/E-cadherin association that
does not lead to b-catenin degradation [20]. More recently,
phosphorylation of b-catenin at Ser45 has been reported to be
spatially separate from phosphorylation at Ser33/37/41 and
appears to be involved in a distinct nuclear function [21]. These
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catenin may not necessarily lead directly to its degradation.
In addition to regulation of b-catenin degradation, APC has
been implicated in a range of cellular processes based on
interactions with cytoskeletal proteins [22,23]. Several of these
functions are altered by cancer-associated APC mutations [22].
However, little is known about the mechanisms by which the
different interactions (and functions) of APC are regulated.
Recently, phosphorylated APC and b-catenin were reported at
microtubule-dependent clusters and phosphorylated APC pro-
posed to play a role in directional migration independent of b-
catenin transcriptional activity or cell-cell adhesion [24]. In the
present study, we establish that N-terminally phosphorylated b-
catenin is localised to distinct subcellular sites in epithelial cells,
including Ca
2+-dependent cell-cell contacts and with APC in
clusters at microtubule ends in cell protrusions. Here, b-catenin
associated with APC exists in a complex that is separate from axin
and is rapidly phosphorylated and dephosphorylated by a GSK3b-
dependent mechanism. Localised phospho-b-catenin/APC clus-
ters accumulate in migrating cells and are lost in colon cancer cells
when APC is truncated. The subpopulation of phospho-b-catenin
at the microtubule tips appears to play a role in the tumour
suppressor function of APC.
Results
b-catenin is phosphorylated at distinct subcellular sites in
epithelial cells
To investigate b-catenin phosphorylation, we examined the
localisation of b-catenin in Madin-Darby Canine Kidney 3
(MDCK) epithelial cells using two phospho-specific b-catenin
antibodies. One antibody was raised against b-catenin phosphor-
ylated on Thr41 and Ser45 [P41/45] and the other was raised
against phosphorylation at Ser33, Ser37 and Thr41 [P33/37/41].
We first confirmed that b-catenin is predominantly localised to cell-
cell contacts in MDCK epithelial monolayers using a pan b-catenin
antibody that recognises all molecular forms of b-catenin [25]
(Layton et al, submitted) (Fig. 1A). b-catenin is reported to be
phosphorylated first on Ser45 by CK1a which creates a priming site
for GSK3b to subsequently phosphorylate Thr41, Ser37 and Ser33
[26,27]. Despite phosphorylation at Ser33 and Ser37 having the
potential to target b-catenin for destruction [6,28,29], stable
populations of phospho-b-catenin recognised by either P41/45 or
P33/37/41 phospho-specific antibodies are found at distinct
subcellular sites, including cell-cell junctions, the mitotic cell
cytoplasm and discrete clusters (Fig. 1B and C). The P33/37/
41-phospho-b-cateninantibodiesalsodetectstainingatcentrosomes
and midbody bridges in mitotic cells and in the nucleus (Fig. 1B
and C). In contrast to previous studies [17] phospho-b-catenin was
detected in the absence of treatments that block the proteasome.
To test the specificity of P41/45- and P33/37/41-phospho-b-
catenin antibodies for the different subpopulations, four control
experiments were employed. Firstly, b-catenin was depleted by
siRNA (,70% reduction; Fig S1). Immunofluorescent staining by
P41/45- and P33/37/41-b-catenin antibodies at cell-cell contacts
and in clusters was markedly reduced in b-catenin depleted cells
(Fig. 1, D–G), indicating that these populations represent
phospho-b-catenin, although the nuclear signal remained, sug-
gesting that it is not specific for phospho-b-catenin. Secondly,
competition with phospho-peptides of the same sequence as the
antigen used to raise phospho-b-catenin antibodies, competed for
detection of distinct subcellular populations by P41/45- and P33/
37/41-b-catenin, with only the nuclear signal remaining, again
suggesting that the nuclear staining may be non-specific (Fig. S2).
Thirdly, phosphorylation of recombinant b-catenin in vitro
demonstrates that P41/45 antibodies recognise b-catenin phos-
phorylated by CK1a alone or CK1a plus GSK3b; P33/37/41
antibodies recognise b-catenin phosphorylated by CK1a plus
GSK3b but not by CK1a nor GSK3b alone (Fig. S3). This data
confirms that CK1a phosphorylates Ser45 while GSK3b is
required for phosphorylation of Thr41, Ser37, Ser33. In addition,
phosphorylation of Thr41 by GSK3b is not necessary for
recognition by the P41/45 antibody, suggesting that it predom-
inantly recognises phospho-Ser45. Neither antibody recognises
unphosphorylated b-catenin (Fig. S3). Finally, neither P41/45-
nor P33/37/41-b-catenin antibodies detect b-catenin in inter-
phase LIM2551 colon cancer cells that harbour a mutation
resulting in deletion of the epitope for the phospho-b-catenin
antibodies (b-catenin residues 5–72 [30]) (Fig. S4A and Fig. S5).
We note that the P33/37/41 phospho-b-catenin antibodies also
stain centrosomes and mid-body bridges in mitotic LIM2551 cells
(Fig. S4B), indicating that the apparent localisation of phospho-b-
catenin at centrosomes and concentrated at the mid-body during
mitosis [19,31] (see Fig. 1C, arrowheads) is not specific for
phospho-b-catenin.
We examined MDCK and 6 colon cancer cell lines and found
that the major band detected by P41/45- and P33/37/41-
phospho-b-catenin antibodies co-migrates with b-catenin (Fig.
S5). Cells containing mutations in APC (LIM2537 and SW480)
have detectable phospho-b-catenin whereas cells containing b-
catenin mutations at Ser45 (LIM1899 and HCT116) do not
contain phospho-b-catenin recognised by P41/45. However, the
P41/45 phospho-b-catenin antibody still recognises T41A b-
catenin (LIM1215) further demonstrating that the P41/45
antibody primarily recognises phospho-Ser45 rather than phos-
pho-Thr41. Interestingly, Ser45 mutant b-catenin, which lacks the
ability to be ‘primed’ for GSK3b phosphorylation by CK1a, is still
recognised by P33/37/41 (Fig. S5), consistent with previous
findings [32], underscoring the complexity of b-catenin regulation.
As expected, inhibition of GSK3b with LiCl did not show a
change in P41/45-b-catenin but does reduce the P33/37/41
signal (Fig. S5). These data suggest that stable populations of N-
terminally phosphorylated b-catenin are associated with different
subcellular sites, and that, in contrast to prevailing models, b-
catenin phosphorylation may not only be involved in degradation.
Phosphorylated-b-catenin localised to cell-cell contacts
requires cell-cell adhesion
We then examined which proteins are associated with
populations of phospho-b-catenin in different subcellular locations.
b-catenin phosphorylated at Thr41 and Ser45 (as detected by the
P41/45 antibody) is localised to cell-cell contacts with E-cadherin
(Fig. 2A). Peripheral P33/37/41-b-catenin staining shows mini-
mal overlap with E-cadherin (Fig. 2B, arrows). The peripheral
phospho-b-catenin localisation is similar to partial co-localisation
with E-cadherin reported previously [18]. E-cadherin co-precip-
itates P41/45-b-catenin whereas P33/37/41-b-catenin is not
detected in the E-cadherin precipitate (Fig. 2C), suggesting that
peripheral P33/37/41-b-catenin may not be associated with cell-
cell adhesions. This may be due to low levels of P33/37/41-b-
catenin and reflect that only a small proportion of total P33/37/
41-phospho-b-catenin may be associated with E-cadherin.
We investigated the nature of peripheral phospho-b-catenin
further by testing the impact of dissociation of calcium dependent
adhesions. Chelation of extracellular calcium disrupts cell-cell
contacts (Fig. 2D and E). Significantly, the peripheral populations
of both P41/45- and P33/37/41-b-catenin are lost completely,
whereas other populations of phospho-b-catenin, notably those in
Phospho-b-Catenin Localisation
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E,arrowheads).Theseresultssuggest thatlocalisationofphospho-b-
catenin to the cell periphery requires intact calcium-dependent cell-
cell adhesions. Furthermore, we do not detect axin at the sites of cell
contact(Fig. S6), in contrast to Maher et al [18], suggesting that the
peripheral, cadherin-associated phospho-b-catenin that we detect is
not part of a destruction complex.
Phosphorylated b-catenin localised with APC at
microtubule ends does not require cell-cell adhesion
Co-staining with APC reveals that P41/45- and P33/37/41-b-
catenin cluster with APC at the ends of microtubules (Fig. 3A and
B, arrowheads, b-tubulin co-stain is shown in, Fig. S7). The
clusters of P33/37/41-b-catenin staining in Fig. 1C (dashed
arrows) are also coincident with APC (not shown). Note that the
majority of APC decorates the ends of microtubules at cell
protrusions in subconfluent epithelial cells, as previously reported
[33].
Given that the phospho-b-catenin populations localised at cell-
cell contacts with E-cadherin and at the ends of microtubules with
APC are spatially separate, and that b-catenin binding to APC and
E-cadherin is mutually exclusive [34], it is clear that the APC/
phospho-b-catenin complex is distinct from the E-cadherin/
phospho-b-catenin complex. E-cadherin co-precipitates P41/45-
Figure 1. Populations of phosphorylated b-catenin in epithelial cells. (A) b-catenin is localised to cell-cell contacts (arrow). Mitotic cell is
indicated by *. (B) Phospho-b-catenin pT41/pT45 (P41/45) is localised to the cell membrane (arrow) and mitotic cell cytoplasm (*). (C) Phospho b-
catenin pS33/pS37/pT41 (P33/37/41) is localised to the cell membrane (arrows), in discrete clusters (dashed arrows) and the mitotic cell cytoplasm (*).
The staining at centrosomes (open arrowheads) and mid-body bridges (filled arrowhead) is indicated. (D–G) MDCK cells were treated with siRNA
directed against b-catenin or a control sequence. Cells were fixed 72 h after siRNA transfection and immunostained with antibodies to P41/45 b-
catenin and b-catenin (D and E) and P33/37/41 b-catenin and b-catenin (F and G). Fields of cells without knockdown (arrows) are shown adjacent to
b-catenin depleted cells (arrowheads) for comparison. Scale bars 20 mm.
doi:10.1371/journal.pone.0014127.g001
Phospho-b-Catenin Localisation
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P33/37/41-b-catenin, but not E-cadherin (Fig. 2C). Accordingly,
the phospho-b-catenin coincident with APC at cell extensions
remains after disruption of calcium-dependent cell-cell adhesion
(Fig. 3C and D, arrowheads) whereas junctional E-cadherin/
phospho-b-catenin is lost. This data suggests that the cell-cell
contact population of phospho-b-catenin (predominantly P41/45)
is associated with E-cadherin in calcium-dependent cell-cell
adhesions and that there is a separate population of phospho-b-
catenin associated with APC clustered at the ends of microtubules
at cell protrusions.
Isolation of APC-rich protrusions
The distinctive localisation of APC to the ends of microtubules
is linked to a role in microtubule stabilisation and cell migration
[35,36]. We focussed on phospho-b-catenin coincident with APC
clusters and sought to isolate APC-rich cell protrusions and
examine the proteins in APC protein complexes. Cells were plated
on a porous 3.0 mm membrane and induced to extend
pseudopodial protrusions through the membrane in response to
a stimulus [37]. We fractionated these cells into pseudopodia (PS)
and cell body (CB) fractions (Fig. 4A). We established that the
protrusions that extend past the lower surface of the membrane in
response to serum stimulation are enriched for APC (Fig. 4B). In
addition, nuclei are not present on the lower surface of the
membrane but were detected only in the cell bodies (Fig. 4B). In
order to isolate sufficient pseudopodial proteins, cells were plated
on the filters at high density. Accordingly, a significant proportion
of cells were not able to extend protrusions to the underside of the
filter, and some APC clusters at the ends of microtubules are still
present on the upper surface of the membrane (Fig. 4B). These
findings indicate that although APC is present at the microtubule
tips on both the upper and lower surfaces of the filter, extraction of
pseudopodia from the lower surface provides a means to
biochemically isolate the APC that is concentrated in protrusions.
We confirmed that APC is present in pseudopodia and cell
bodies by immunoblotting isolated CB and PS fractions (Fig. 4C,
D). In the absence of serum, little APC, as well as b-tubulin, is
detected in the pseudopodia fraction (data not shown), consistent
with immunofluorescent staining (Fig. 4B) and indicating that
serum is required for pseudopodia formation and/or extension.
The isolated pseudopodia fraction contained only low level
contamination of proteins exclusive to the cell body. No nuclear
staining (DAPI) was apparent in the pseudopodia (Fig. 4B)
therefore no nucleoporin, a nuclear membrane protein, should
appear in the PS fraction (Fig. 4C, D). The contribution of CB
proteins to the PS fraction is therefore defined by the proportion of
nucleoporin in the PS (Fig. 4D). Proteins with a greater
proportion in the PS versus the CB fraction compared to
nucleoporin are therefore enriched in pseudopodia or distributed
similarly between the two fractions. Importantly, proteins with a
lower proportion in the PS compared to nucleoporin must be
excluded from the pseudopodia.
APC/b-catenin in cell protrusions is distinct from the
APC/b-catenin/axin complex
A significant proportion of total b-catenin is present in the
pseudopodia, together with E-cadherin (Fig. 4C, D). E-cadherin
and b-catenin are also detected in the PS fraction by immuno-
fluorescence (not shown). As expected, b-tubulin and actin are also
present in pseudopodia (Fig. 4C, D). We next examined proteins
shown to associate with APC and b-catenin in the ‘destruction
complex’. Consistent with our previous findings [38], only a very
small proportion of axin is present in the pseudopodia compared
to the cell bodies (less than 4-fold compared to APC, P,0.002),
suggesting that any axin:APC complex is spatially separate from
APC concentrated in cell protrusions (Fig. 4C, D). Moreover, the
proportion of axin in the PS fraction was consistently less than the
proportion of nucleoporin in the PS fraction, indicating that any
axin detected in this fraction must be due to low level CB
contamination of the PS fraction (Fig. 4D). The proportion of
APC, b-catenin, GSK3b and CK1a, as well as PP2A (not shown),
detected in the PS fraction was consistently greater than that of
nucleoporin (Fig. 4C, D), demonstrating that they are genuinely
present, although not necessarily enriched in pseudopodia. Thus
the APC/b-catenin complex in cell protrusions is distinct from the
APC/axin/b-catenin destruction complex.
b-catenin associated with APC at the ends of
microtubules is phosphorylated by GSK3b
To test whether the different subpopulations of N-terminally
phosphorylated b-catenin are GSK3b-dependent, we treated cells
with two different GSK3b inhibitors. Both kenpaullone and LiCl
treatment results in loss of APC-coincident P33/37/41 b-catenin
clusters (Fig. 5A and B) indicating that b-catenin is phosphor-
ylated by GSK3b at this site. Reduction in P33/37/41 b-catenin
following kenpaullone and LiCl treatment was confirmed by
immunoblot analysis (Fig. S8A). P41/45 b-catenin is not affected
by GSK3b inhibitors, as expected (Fig. S8B and C). The
localisation of P41/45 b-catenin with APC clusters implies that
phosphorylation at Ser33, Ser37 and Thr41 by GSK3b does not
result in recruitment of b-catenin to APC clusters, but instead that
b-catenin resident in these complexes is phosphorylated by
GSK3b in situ. Surprisingly, the P33/37/41 b-catenin at cell
contacts is not affected by inhibition of GSK3b even after long
treatments (Fig. 5A and B) suggesting that GSK3b is not involved
in phosphorylating these populations of b-catenin. Both P33/37/
41- and P41/45-b-catenin at cell-cell contacts are reduced
following treatment with CK1 inhibitor, D4476 (Fig. S8A and
B; Fig. S9). The loss of P33/37/41- and P41/45-b-catenin cell
contact staining upon CK1 but not GSK3b inhibition (Fig. S9)
indicates that CK1, but not GSK3b, is involved in b-catenin
phosphorylation at cell-cell adhesions. This implies that either
CK1 phosphorylates P33/37/41 localised at the cell periphery or
that S45 phosphorylation is required for these sites to be
phosphorylated by another priming-dependent kinase. Thus, b-
catenin is phosphorylated both by CK1 and GSK3b, but is
Figure 2. Phosphorylated b-catenin associates with E-cadherin at cell-cell adherens junctions. (A) P41/45-b-catenin is localised to cell-cell
contacts with E-cadherin. (B) P33/37/41-b-catenin is localised to the cell periphery and shows partial overlap with E-cadherin. Cell contacts are
indicated by arrows. Inset, enlarged view of overlapping phospho-b-catenin (green) and E-cadherin (red). P41/45-b-catenin (A) shows more
prominent cell contact staining and overlap with E-cadherin than P33/37/41-b-catenin (B). (C) Co-precipitation of phospho-b-catenin with E-cadherin
and APC in MDCK cells. APC, E-cadherin, P41/45- and P33/37/41-b-catenin immunoprecipitates were immuno-blotted with the indicated antibodies.
* denotes non-specific band. (D and E) Peripheral phospho-b-catenin is regulated by Ca
2+-dependent cell-cell contact. Cell contact associated E-
cadherin and phospho-b-catenin staining is intact in control cells (arrows), but disrupted in treated cells where phospho b-catenin clusters remain
(arrowheads). Phospho-b-catenin (green), E-cadherin (red), nuclei (DAPI) blue. Shown are representatives of at least three different experiments; scale
bars 20 mm.
doi:10.1371/journal.pone.0014127.g002
Phospho-b-Catenin Localisation
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cellular sites.
In astrocytes, GSK3b has been reported to be specifically
inactivated in cell protrusions, leading to the association of APC
with the plus ends of microtubules [39]. Accumulation of b-
catenin at the leading edge in these cells is attributed to the
localised inhibition of GSK3b. Although our observations suggest
that APC localisation to the ends of microtubules is unaffected by
inhibition of GSK3b and that the b-catenin which accumulates
with APC is phosphorylated by GSK3b, and is unaffected by
degradation, it is possible that these are separate events and that
examining total b-catenin masks the phospho-specific events. In
addition, the rate of phosphorylation and the incubation period for
inhibitors may be crucial. The role of GSK3b is complex and
short term LiCl treatment (up to 4 h) has been reported to result in
dramatically different effects on b-catenin compared to longer
term inhibition (.6 h) (Gottardi and Gumbiner, 2004).
Consequently, we examined the kinetics of GSK3b-dependent
phosphorylation of localised b-catenin in lysates from control or
LiCl treated cells. Inhibition of GSK3b for one hour results in
reduced P33/37/41-b-catenin and this persists for several hours
with LiCl treatment before phosphorylation begins to be restored
(Fig. 5C). The P33/37/41-b-catenin co-precipitated with APC is
also reduced in GSK3b inhibited cells compared to control,
whereas total b-catenin is similar in control and treated cells
(Fig. 5C). P41/45-b-catenin is not altered in LiCl-treated cells
(Fig. 5C and Fig. S8), which suggests that the loss of phospho-b-
catenin upon GSK3b-inhibition is not due to protein turnover/
degradation. P33/37/41-b-catenin coincident with APC at the
ends of microtubules is reduced within 5 min of LiCl treatment
and is depleted for several hours (Fig. 5D), consistent with
immunoblot analysis of total lysates and APC immunoprecipitates
(Fig. 5C). The APC clusters themselves were not affected by
Lithium treatment, although the number of clusters per cell was
reduced with longer treatments (.6h )( Fig. 5D). These data show
that b-catenin localised with APC at the ends of microtubules is
phosphorylated by GSK3b and that inhibition of GSK3b or CK1
does not have a marked effect on APC clusters.
b-catenin associated with APC is phosphorylated and
dephosphorylated rapidly
To investigate phosphorylation of b-catenin by GSK3b further,
we first inhibited GSK3b by pretreatment with LiCl and then
washed out the inhibitor and assessed P33/37/41-b-catenin levels.
Consistent with rapid phosphorylation, P33/37/41-b-catenin
increases after removal of LiCl from the media (Fig. 5E, Fig.
S10A). P33/37/41-b-catenin co-incident with APC is also
increased (Fig. S10C (P,0.02)). The rapid loss of phosphoryla-
tion upon treatment with LiCl indicates that a phosphatase may
directly regulate b-catenin, as suggested in earlier studies [17].
While we observe only modest increases in P33/37/41-b-catenin
in total cell lysates upon incubation with phosphatase inhibitors
(Fig. S10B), there is a robust increase in the proportion of P33/
37/41-b-catenin co-incident with APC (Fig. S10C (P,0.0001)).
Interpretation of these experiments is complicated by any direct
effects of phosphatase inhibitors and LiCl treatment on the auto-
inhibitory Ser9 phosphorylation of GSK3b as has been reported
[40], however, these data suggest that the phospho-b-catenin
localised at the ends of microtubules is also regulated by
phosphatases. Together, these data suggest that phospho-b-catenin
observed in clusters at cell protrusions is associated with APC and
constantly phosphorylated by GSK3b, and that other subpopu-
lations of phospho-b-catenin at other subcellular sites are likely to
be phosphorylated by other kinases.
Phospho-b-catenin localisation is prominent at the ends
of microtubules in migrating cells
Given that APC localised to the plus ends of microtubules is
implicated in microtubule dynamics and cell migration [36,41,42],
we examined phospho-b-catenin in cells stimulated to migrate in a
scratch wound assay. In subconfluent MDCK cells, APC is
localised to the ends of a subset of microtubules, often in cell
protrusions ([36,42], see also Fig. 3B). One to two hours after
wound-induced migration, P33/37/41-b-catenin accumulates in
clusters at the leading edge of migrating cells (Fig. 6A) where APC
also decorates the ends of microtubules (Fig. 6B). Importantly,
P33/37/41-b-catenin accumulates with APC at the leading edge
of migrating cells (Fig. 6B).
The accumulation of phospho-b-catenin in association with
APC in migrating cells prompted us to examine the location of
P33/37/41-b-catenin in cells stimulated with HGF. HGF
stimulates epithelial cell motility, inducing disruption of cell-cell
junctions and subsequent cell scattering [43]. In control cells, P33/
37/41-b-catenin is concentrated at the ends of microtubules
coincident with APC (Fig. 6C). HGF stimulation results in
extended protrusion formation and prominent P33/37/41 b-
catenin and APC staining at the ends of microtubules in these
protrusions (Fig. 6D). Thus, induction of cell migration promotes
the accumulation of phospho-b-catenin and APC at the leading
edge. Whether phosphorylation of b-catenin at the ends of
microtubules contributes to the process of cell migration or
whether this occurs as a result of cell migration remains to be
determined. Interestingly, phosphorylation of b-catenin at the
microtubule ends in migrating epithelial cells contrasts with that
observed in migrating astrocytes where GSK3b is inactivated at
the leading edge [39].
Phospho-b-catenin clusters localised to the ends of
microtubules is dependent on APC
We then tested whether loss of APC impacts phospho-b-catenin
localised to the ends of microtubules by depleting APC with
siRNA. Transfection of MDCK cells with siRNAs targeting APC
reduces the level of APC (Fig. 7A) and results in loss of detectable
P33/37/41-b-catenin clusters at the ends of microtubules
(Fig. 7B). Quantification of phospho-b-catenin at microtubule
protusions revealed a significant reduction in phospho-b-catenin
clusters in APC siRNA treated cells compared to control
(P,0.001) (Fig. 7C). E-cadherin staining defines the junctional
signal in MDCK colonies and shows that concentrations of P33/
37/41-b-catenin coincident with E-cadherin are unaffected in
APC siRNA treated cells (Fig. S11, green arrows). Note that these
accumulations of P33/37/41 are not coincident with APC.
To test the significance of APC in phospho-b-catenin
localisation at cell extensions, we examined P33/37/41-b-
Figure 3. Phosphorylated b-catenin associates with APC at the ends of microtubules. (A and B) Phosphorylated b-catenin is localised in
clusters with APC in MDCK cells. Coincident APC (magenta) and phospho-b-catenin (green) is indicated with arrowheads. (C and D) Disruption of
Ca
2+-dependent cell-cell contact does not alter phospho-b-catenin coincident with APC in clusters at cell extensions (arrowheads). Junctional
phospho-b-catenin staining is intact in control cells (arrows). Phospho-b-catenin (green), APC (red), nuclei (DAPI) blue. Shown are representatives of
at least three different experiments; scale bars 20 mm.
doi:10.1371/journal.pone.0014127.g003
Phospho-b-Catenin Localisation
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APC. LIM2405 cells contain a single intact APC allele and
harbour a mutation in the other allele which results in truncation
at residue 2198 [30]. LIM2405 cells form loosely adherent
colonies with the cells on the outer edges extending prominent
protrusionsthataredecoratedattheveryends byAPC (Fig. 7D).
P33/37/41-b-catenin also accumulates at the ends of these
protrusions (Fig. 7D, white arrowheads) and is also frequently
found in concentrations immediately before the ends of the
extension (Fig.7D, green arrowheads). SW480 cells contain only
truncated APC,and in contrastto cells with intactAPC, P33/37/
41-b-catenin is not detected at the ends of microtubules, but is
instead distributed diffusely throughout the cytoplasm (Fig. 7E).
Together these data show that intact APC is required for
Figure 4. Isolation of APC from protruding pseduopodia. (A) Schematic diagram depicting strategy for isolation of pseudopodia. PS
pseudopodia, CB cell bodies. (B) MDCK cells on 3.0 mm pore filters were induced to extend pseudopodial protrusions. Cells were fixed and either cell
bodies were removed leaving pseudopodia, bottom (PS), or pseduopodia were removed leaving cell bodies, top (CB). Filters were immunostained for
APC (green) and b-tubulin (red) and costained with DAPI (blue).Cells protrusions contain APC. DAPI staining confirms there are no nuclei on the lower
surface, bottom (PS). Scale bar, 20 mm. (C) Isolation of APC and b-catenin, but not axin, from the pseudopodia (PS) fraction. Immunoblots of proteins
isolated from the pseudopodia (PS) on the lower membrane surface or cell bodies (CB) on the upper membrane surface of 3.0 mm pore filters. Total
protein loaded was 12 mg except for the P41/45 and P33/37/41 immunoblots where 50 mg CB was loaded in order to detect the proteins. The
numbers to the side of blots are the normalised ratio of the amount of each protein in PS vs CB. Shown is representative from at least 3 independent
experiments. (D) APC, but not axin, is present in the PS fraction. Proteins isolated from the PS or CB fractions were resolved by SDS-PAGE and
immunoblotted as in (C). Shown is the average +/2 SEM of the ratio of PS:CB for the indicated protein from at least three separate experiments (n is
indicated). ***P,0.002, *P,0.05 by Student’s t-test.
doi:10.1371/journal.pone.0014127.g004
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PLoS ONE | www.plosone.org 8 November 2010 | Volume 5 | Issue 11 | e14127Figure 5. Inhibition of GSK3b results in loss of P33/37/41-b-catenin associated with APC but not other sub-populations. (A)
Kenpaullone (2 nM, 30 min) and (B) LiCl (30 mM, 5 min) treatment of MDCK cells results in loss of P33/37/41-b-catenin coincident with APC. APC
clusters (arrowheads) are coincident with P33/37/41-b-catenin in control but not kenpaullone or LiCl treated cells; intact peripheral staining is
indicated by arrows. Scale bars 20 mm. (C) LiCl treatment results in reduced P33/37/41-b-catenin in total cell lysates and associated with APC, but not
P41/45-b-catenin. Lysates from MDCK cells treated with 30 mM NaCl or LiCl for T0, 1, 2, 6 and 24 h were immunoblotted or immunoprecipitated with
APC antibodies and immunoblotted as indicated. Overlay refers to the merge of P33/37/41 or P41/45-anti-rabbit-IR800 and b-catenin-anti-mouse-
IR680 channels. (D) Analysis of coincident P33/37/41-b-catenin and APC clusters following GSK3b inhibition. MDCK cells were treated with 30 mM
NaCl or LiCl for the indicated times, fixed and immunostained. Cells were scored for coincident P33/37/41-b-catenin and APC clusters (left) and
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microtubules protrusions.
Discussion
b-catenin is a critical component of cell-cell adhesions, where it
forms a dynamic link between E-cadherin and the actin
cytoskeleton [44,45]. It is also a critical component of Wnt
signalling, where it functions as a transcriptional activator of target
genes that regulate cell proliferation and differentiation [15]. The
canonical model of Wnt signalling requires that N-terminally
phosphorylated b-catenin is targeted for destruction, thus
providing a means for regulating the transcriptionally active
protein. Our present findings establish that the different
subcellular populations of N-terminally phosphorylated b-catenin
are regulated quite differently and that phosphorylated b-catenin
is not always targeted for destruction: 1. Phospho-b-catenin is
detected without blocking the proteasome; 2. Mutation of S45 still
results in detection of phospho-S33/S37/T41, as previously
shown [32]; 3. Distinct subcellular locations of phospho-b-catenin
implies participation in different functions; 4. Inhibition of GSK3b
reduces the phospho-b-catenin at cell protrusions but does not
appear to alter the junctional phospho-b-catenin populations; 5. A
core component of the destruction complex, axin, is not present in
cell protrusions with APC and is not detected at cell-cell junctions;
6. Accumulation of APC and phospho-b-catenin at the ends of cell
protrusions and at the leading edge of migrating cells suggests that
this population has an active role in microtubule regulation, cell-
cell or cell matrix interactions. Our data suggest that localised
phospho-b-catenin has distinct roles in normal epithelial cells
(Fig. 8) and that the truncation of APC in many colon cancers
would be expected to disturb these functions.
N-terminally phosphorylated b-catenin localised to sites of cell-
cell contact is associated with E-cadherin and requires intact cell-
cell adhesions. Phospho-b-catenin has recently been reported in
two separate complexes: one with E-cadherin and the other with
components of the destruction complex [18]. Cell-cell adhesion is
proposed to influence the activity of the Wnt-signalling pool of b-
catenin via a junction-localised phospho-destruction complex [18].
The loss of cell contact phospho-b-catenin that we observe
following perturbation of Ca
2+-dependent cell adhesion may
reflect the increased transcriptionally active b-catenin reported by
Maher et al [18]. However, we did not detect any change in the
levels of total b-catenin (MCF and JLC, unpublished data),
consistent with a recent report that also showed that the
proteosomal inhibitor MG132 had little effect on b-catenin
phosphorylation or Tcf/Lef-mediated transcription [24]. Signifi-
cantly, we did not detect other destruction complex components
(i.e. axin) at the cell periphery. Our results show that N-terminally
phosphorylated b-catenin is not exclusively present in the
destruction complex. Further, inhibition of GSK3b did not alter
the cell-cell adhesion-associated populations of P41/45- or P33/
37/41-b-catenin, indicating that this population of P33/37/41-b-
catenin is likely to be phosphorylated by another kinase. This
contrasts with the recent findings in endothelial cells that
inhibition of GSK3b and CK1a results in reduced phospho-b-
catenin at cell-cell contacts and in this cell type phospho-b-catenin
was not detected in VE-cadherin immunoprecipitates [24]. The
loss of cell contact phospho-b-catenin following CK1 inhibition
implicates CK1 in the phosphorylation of b-catenin at Ser45 and
possibly also Ser33/Ser37/Thr41. Alternatively, CK1 may be
required to prime b-catenin at Ser45 for phosphorylation at
Ser33/Ser37/Thr41 by another kinase. As recently proposed,
phosphorylation at S45 may not only be important for priming b-
catenin for subsequent phosphorylation [21]. Although P33/37/
41-b-catenin is present at cell contacts in a Ca
2+-dependent
manner, it does not associate with E-cadherin by immunopreci-
piation analysis, supporting the conclusion from Maher et al. [21]
that P33/37/41-b-catenin can be uncoupled from P41/45. While
tyrosine phosphorylation of b-catenin is reported to reduce E-
cadherin-b-catenin association at the membrane [46], the role of
N-terminally Ser/Thr phosphorylated b-catenin at the cell
junctions remains an open question. Adherens junctions are
dynamically modulated [44,45] and while N-terminally phosphor-
ylated b-catenin may not be necessary for stable cell-cell
adhesions, it may be required for junction formation [17] or
recycling [47]. Interestingly, Wnt5a was recently proposed to
promote b-catenin/E-cadherin association via CK1a-mediated
phosphorylation of b-catenin at Ser45 but not Ser33 [20] which
supports a role for Ser45 phospho-b-catenin in cell adhesion and
also raises the possibility that localised phosphorylation at
individual sites may lead to distinct functional outcomes.
The striking cytoplasmic distribution of phospho-b-catenin in
mitotic cells, particularly for P41/45-b-catenin, suggests a role in
cell-cycle regulation. Total b-catenin levels are reported to
increase in early S phase and are maximal at G2/M [48], but
the increase in the phospho-b-catenin is much more dramatic than
any increase in the total b-catenin levels. However, it has been
shown that many proteins become highly phosphorylated during
M phase [49], therefore it is not yet clear whether N-terminal
phosphorylation of this population of b-catenin is functional or
whether it is a bystander phosphorylation.
Our discovery that phospho-b-catenin accumulates with APC
clusters at the ends of microtubules reveals an unexpected role for
b-catenin in conjunction with microtubule-associated APC. APC
localisation to the plus ends of growing microtubules is well
established [33,42] and is linked to its role in cell migration,
polarization and microtubule stability [23]. While b-catenin and
stabilised b-catenin mutants have been reported to be associated
with peripheral APC clusters [33,50,51,52], its role at this location
is not entirely clear. Conflicting reports have suggested that b-
catenin contributes to accumulation of APC at membrane clusters
[52] or interferes with APC function [51]. In addition, it is not
known whether the multiple complexes that APC participates in
exist in concert or as distinct complexes. A recent report indicates
that phospho-b-catenin is also localised in clusters at microtubule
ends in endothelial cells and that CK1- and GSK3b-mediated
phosphorylation of APC, but not b-catenin, appears to promote
cell migration in a process that is independent of b-catenin-
mediated transcription [24]. Our results support this notion except
that in endothelial cells, APC clusters appeared to be linked to the
proteasomal degradation of APC and b-catenin [24]. Since we
have shown that extending pseudopodia contain APC, but not
axin, it is clear that the APC at microtubule extensions is distinct
from the axin-APC complex [38,53] in epithelial cells. Unlike
number of APC clusters/cell (right). Shown is average +/2 SEM from three (T0, 5 min, 1, 2 6 and 24 h) or two (T30 min) independent experiments,
.100 cells per treatment group; ***P,0.001, **P,0.01 by Student’s t-test. (E) Removal of GSK3b inhibition allows re-phosphorylation of b-catenin.
MDCK cells pretreated with 30 mM NaCl or LiCl for 30 min, were incubated in DME+10%FCS and harvested at T0, 5, 10 and 20 min. Lysates were
immunoblotted with P33/37/41 b-catenin and actin antibodies. Shown is average +/2 SEM from four independent experiments for normalised
densitometry values, *P,0.05, **P,0.01 by Student’s t-test. A representative blot is shown in Fig S10A.
doi:10.1371/journal.pone.0014127.g005
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PLoS ONE | www.plosone.org 11 November 2010 | Volume 5 | Issue 11 | e14127endothelial cells, APC is not present at the lateral membrane in
MDCK cells. Furthermore, we have shown that phospho-b-
catenin is localised to Ca
2+-dependent cell contacts and forms a
complex with E-cadherin whereas phospho-b-catenin was not
detected in VE-cadherin complexes [24], underscoring the
differences between the cell types which may explain the different
conclusions.
We propose that the form of N-terminally phosphorylated b-
catenin which accumulates with APC at cell extensions is not
targeted for degradation but may regulate microtubule-associated
APC function. Stabilised b-catenin has previously been implicated
in inhibition of APC function in neurite formation and growth
[51]. However, we did not detect altered APC at microtubule
extensions upon inhibition of b-catenin phosphorylation. Our data
suggest that unlike stabilised b-catenin, phospho-b-catenin does
not impede APC function at microtubules.
Our experiments show that GSK3b phosphorylates the b-
catenin that accumulates with APC at microtubule ends. The
action of GSK3b is intriguing. GSK3b phosphorylation of APC is
reported to abolish microtubule binding [54] and localised
inactivation of GSK3b in migrating astrocytes and neurite
extensions leads to accumulation of APC in cell polarisation and
axon growth, respectively [39,55]. In contrast, Wnt-induced
GSK3b inactivation in neuronal growth cones, and CK1- and
GSK3b-inhibition in endothelial cells, leads to decreased APC at
microtubule plus ends [24,56]. Different levels of GSK3b
inhibition are proposed to exert different responses depending
on cell context or cell type [14,56]. We observed reduced
phospho-b-catenin associated with APC in epithelial cells within
5 min of GSK3b inhibition, indicating that turnover of phos-
phorylation at these sites is rapid, and this was maintained during
6 h of treatment. We did not observe changes in APC clusters
during this time frame. In contrast, previous reports identified
accumulation of APC after 8 h to 24 h treatments [55,57]. We
also show prominent accumulation of phospho-b-catenin with
APC at the leading edge of cells stimulated to migrate for 1–2 h
indicating that GSK3b phosphorylates b-catenin associated with
APC in migrating cells. While depletion of b-catenin did not result
in differences in endothelial cell migration upon GSK3b inhibition
[24], b-catenin has been strongly implicated in epithelial cell
migration [58] and our current results link phospho-b-catenin to
APC migration/adhesion processes that are independent of axin
and b-catenin degradation. Thus GSK3b is important in
regulating APC at microtubules, but is also involved in
phosphorylation of b-catenin. As functional APC is required for
localised phospho-b-catenin at cell protrusions, this process must
also involve APC.
The rapid loss of phospho-b-catenin at the protrusion tips
following GSK3b inhibition suggests the presence of a phospha-
tase, as proposed in an earlier study [17]. PP2A has been linked to
b-catenin and the degradation complex [59,60,61], where APC
has been proposed to protect phosphorylated b-catenin from
PP2A dephosphorylation thus enabling it to be ubiquitinated and
degraded [62]. Whether APC plays a similar role at microtubule
plus ends remains to be determined, but we did detect significant
levels of PP2A in isolated pseudopodia (MCF, unpublished) and
inhibition of PP2A resulted in increased phospho-b-catenin
staining in clusters coincident with APC. Identifying the molecular
mechanisms that regulate localised phosphorylation of b-catenin at
the microtubules will be an important challenge in the future.
While our data showing that axin is excluded from APC-rich
protrusions suggests that phospho-b-catenin is not always targeted
for proteasomal-mediated destruction, we cannot rule out a model
whereby phosphorylation of b-catenin earmarks the protein for
destruction by non-axin-mediated mechanisms. One such scaffold
complex, containing presenilin, has previously been implicated in
mediating phosphorylation of b-catenin [63]. However, while
treatment with proteasome inhibitors increases the levels of
phospho-b-catenin co-incident with axin puncta [38], clearly
demonstrating regulation of these populations by proteasomal
degradation, we observed no similar increase in the levels of the
APC-rich protrusions-associated population of phospho-b-catenin
due to treatment with proteasome inhibitors. Instead, the
population associated with APC is prominent in actively migrating
cells, implying that it has an active role in cell migration. Although
surprising, our data also shows that kinases other than the CK1a/
GSK3b combination can phosphorylate b-catenin, which may
result in b-catenin destruction or mark distinct functions, such as
in cell migration and/or adhesion processes. It should be noted
that the rapid dephosphorylation of b-catenin in the presence of
GSK3b inhibitors is also reversed rapidly when the inhibition is
removed, suggesting that the b-catenin in the protrusions may not
be destroyed.
Overall, our studies implicate phosphorylated b-catenin in cell
adhesion and at the ends of APC-associated HGF- and wound
healing-induced cell protrusions. The latter process requires
functional APC and is perturbed in cancer cells containing
mutated APC (Fig. 7). Regulation of localised phospho-b-catenin
may contribute to the tumour suppressor activity of APC. Whether
accumulation of APC and phospho-b-catenin at the leading edge
is controlled by Wnt signalling will require further investigation.
We propose that phosphorylation of b-catenin does not only lead
to its degradation but provides a level of regulation for b-catenin
function in distinct cellular processes. This premise is supported by
our recent identification of the formation of a Wnt3a-induced
phospho-b-catenin-APC-a-catenin complex that resides close to
the plasma membrane and appears to be involved in cell-cell
adhesion (Layton et al., submitted). The demonstration of localised
phosphorylated forms of b-catenin provides important insight into
understanding the complexities of b-catenin signalling in colon
cancer.
Materials and Methods
Antibodies
The anti-phospho-b-catenin P41/45 and P33/37/41 antibodies
were from Cell Signaling (9565 and 9561, respectively). The APC
monoclonal antibody (APC-NT) was raised against amino acids 1–
61 of human APC with an N-terminal Flag epitope tag, produced
in bacteria (Elliott, Catimel and Faux, unpublished). Commercial
antibodies were obtained from Santa Cruz (anti-APC (H290) and
CK1a), Zymed (axin-1), BD Transduction Laboratories (b-catenin
Figure 6. Phospho-b-catenin and APC are localised to the ends of microtubules in migrating cells. (A) P33/37/41-b-catenin in clusters at
the wound edge. Representative images of cells fixed at T=0 (left) and 2 hours after wounding. P33/37/41-b-catenin (green), b-tubulin (red), DAPI
(blue). Scale 20 mm; inset 10 mm. (B) P33/37/41-b-catenin and APC in migrating MDCK cells. Merged image shows coincident (white) P33/37/41-b-
catenin (green) and APC (magenta) at the ends of microtubules (b-tubulin, blue). Nuclei were visualised with TO-PRO-3 iodide staining (cyan). Scale
10 mm. Insets show enlarged view of the leading edge of migrating cells. Scale bar 5 mm. (C and D) MDCK cells were serum starved and untreated (C)
or stimulated with 2 ng/ml HGF for 6 h (D) and immunostained with antibodies to P33/37/41-b-catenin (green), APC (magenta) and b-tubulin (blue).
Scale 10 mm. Insets show clusters at microtubule ends that are highly concentrated in HGF treated cells. Scale bar 5 mm.
doi:10.1371/journal.pone.0014127.g006
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PLoS ONE | www.plosone.org 12 November 2010 | Volume 5 | Issue 11 | e14127Figure 7. APC is required for phospho-b-catenin localisation to the ends of microtubules. (A) Depletion of cellular APC by siRNA. APC
levels following siRNA transfection were assessed by immunoblot analysis in cell lysates. Actin was used as a loading control. (B) MDCK cells
transfected with control and APC siRNA were immunostained for P33/37/41-b-catenin (green), APC (cyan) and b-tubulin (red) with APC/b-tubulin and
P33/37/41-b-catenin/b-tubulin enlarged in insets shown below. Arrowheads indicate clusters of phospho-b-catenin at microtubule ends coincident
with APC in control but not APC depleted cells. Scale bars 20 mm. (C) Quantification of phospho-b-catenin clusters (%) at microtubule protrusions in
control and APC siRNA treated cells. Shown is average +/2 SD from 3 independent experiments, .70 microtubule protrusions per treatment group.
***P,0.001 by Student’s t-test. (D) LIM2405 colon cancer cells containing a wt APC allele demonstrate concentrations of P33/37/41-b-catenin (green)
at cell extensions that partially overlap with APC (magenta) (white arrowheads indicate overlap with APC, green arrowheads indicate concentrations
of P33/37/41-b-catenin that do not overlap with APC). Nuclei were visualised with DAPI; scale bars 10 mm. (E) P33/37/41-b-catenin is diffusely
cytoplasmic in SW480 colon cancer cells and does not concentrate in clusters at microtubule ends. SW480 cells were immunostained with P33/37/41-
b-catenin (green) and b-tubulin (red) and costained with DAPI to visualise nuclei, scale bar 20 mm. P33/37/41/b-tubulin and P33/37/41-b-catenin
enlarged in insets are shown below, scale bar 10 mm.
doi:10.1371/journal.pone.0014127.g007
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PP2A), and Sigma (actin, clone AC-40 and b-tubulin, clone 2.1).
AlexaFluor-conjugated secondary antibodies were from Molecular
Probes and IR Dye-conjugated secondary antibodies were from
LiCor Biosciences.
Cell culture and treatments
MDCK cells [64] were grown in DMEM supplemented with
10% foetal calf serum (FCS) (DMEM+10%FCS) and 1%
penicillin/streptomycin. Colorectal carcinoma cell lines SW480
[65], HCT116 and LIM cells: LIM2405 [66], LIM2537,
LIM1215, LIM1899, LIM2551 [30] were grown in RPMI
supplemented with 0.01 mg/ml thioglycerol, 0.025 U/ml insulin,
1 mg/ml hydrocortisone, 10% FCS and 1% penicillin/
streptomycin.
For Ca
2+ chelation experiments, MDCK cells were serum
starved for 24 h and incubated with 4 mM EGTA, 1 mM MgCl2
in DMEM or control DMEM for 2 h. For GSK3b inhibitor
experiments, cells were incubated with 2 nM Kenpaullone
(Calbiochem) or dimethyl sulfoxide (DMSO) control, 30 mM
LiCl or 30 mM NaCl, for the indicated times. For inhibition of
CK1, cells were incubated with 100 mM D4476 (Calbiochem)
diluted as described [67] and 5–10 mM IC261 (Calbiochem) or
dimethyl sulfoxide (DMSO) control. For inhibitor washout
experiments, MDCK cells were pretreated with 30 mM LiCl or
NaCl for 30 min, cells were washed 26 and incubated with
DMEM+10%FCS for 0, 5, 10 and 20 min. Scratch wound assays
were performed by plating MDCK cells on optical glass coverslips.
Confluent monolayers were scratched with a plastic tip, washed
26 DMEM and incubated with DMEM +10%FCS. The cells
Figure 8. Functionally distinct populations of N-terminally phosphorylated b-catenin. P41/45-b-catenin associates with E-cadherin at cell-
cell contacts. P33/37/41-b-catenin is also found at Ca
2+-dependent cell contacts but is not detected in the complex with E-cadherin. P41/45- and P33/
37/41-b-catenin associate with APC at the ends of microtubules at the leading edge of migrating cells. At the protrusions the phospho-b-catenin is
rapidly phosphorylated and dephosphorylated. This complex is separate from the axin destruction complex that targets phospho-b-catenin for
proteasomal degradation.
doi:10.1371/journal.pone.0014127.g008
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were serum starved for 24 h and incubated with 2 ng/ml HGF (R
and D Systems) for 6 h.
To deplete APC using RNA interference (RNAi), MDCK cells
were transfected with small interfering RNA (siRNA) directed
against APC with Lipofectamine 2000 (Invitrogen, Carlsbad, CA,
USA) according to manufacturer’s instructions using 0.3 mM
siRNA targeting canine APC (Ambion) or 0.3 mM non-targeting
siRNA. Predesigned Dharmacon siRNA pools targeting b-catenin
(CTNNB1, L-003482-00-0005, NM_001904) and non-target
control siRNA pools (D-001810-20) were used to deplete b-
catenin in MDCK cells. Cells were harvested for immunoblot
analysis or fixed for immunofluorescence 48 h after siRNA
treatment. The sequences of siRNA oligonucleotides were: siAPC
1: 59-GGAAUCAACCCUCAAAAGUtt-39, siAPC 2: 59-GCA-
CACUGCACUGAGAAUAtt-39, siAPC 3 59-GCACACUGCA-
CUGAGAAUAtt-39 (Ambion).
Confocal fluorescence microscopy
Cells were immunostained as described previously [68] with the
indicated primary antibodies. AlexaFluor488-, 546-, 633- and 405-
conjugated secondary antibodies were used for immunofluores-
cence analysis. For peptide competition experiments, P41/45 and
P33/37/41 phospho-b-catenin antibodies were preincubated
without and with P41/45 and P33/37/41 peptides (Cell
Signalling), respectively, for 30 min. For immunostaining with
antibodies raised in the same species, cells were first incubated
with APC (APC-NT) mouse monoclonal antibodies for 1 hour,
washed 36 0.2%BSA/PBS, incubated with anti-mouse Alexa-
Fluor-546 antibodies for 1 h, and then washed 460.2% BSA/PBS
before incubating with b-tubulin or E-cadherin mouse monoclonal
antibodies for 1 h. Cells were washed 360.2% BSA/PBS and
incubated with anti-mouse AlexaFluor-405 antibodies for 1 h,
washed 360.2% BSA/PBS. Cells were co-stained with DAPI or
TO-PRO-3 Iodide (642/661 Molecular Probes) to visualise nuclei.
Immunofluorescence staining was detected in successive focal
planes using Nikon C1 or Olympus FV1000 confocal microscopes.
Double- and triple- labelled images were detected using standard
filter sets and laser lines. Cells were imaged with Nikon Plan Apo
606 (NA1.4), Nikon TIRF 1006 (NA1.45), Olympus 606
(NA1.35) oil or Olympus 606(NA1.35) water immersion lenses.
Co-immunoprecipitation and immunoblot analysis
MDCK cells were lysed in ice-cold Lysis Buffer (20 mM HEPES,
pH7.4 containing 150 mM NaCl, 5 mM EDTA, 1% Na deoxycho-
late, 1% Triton-X100, a phosphatase inhibitor cocktail (1 mM Na
Vanadate, 10 mM NaF, 5 mM Na pyrophosphate, 5 mM b-
glyercophosphate, 10 nM okadaic acid), and Complete (Roche)
EDTA-free protease inhibitor cocktail). Lysates were clarified by
microcentrifugation at 16,000 g for 30 min at 4uC. For immunopre-
cipitations, the lysates were incubated with the indicated antibodies
(1–2 mg) for 16 h at 4uC and with protein A- or G-Sepharose (10%
slurry) (Pharmacia) for the final 30 min 4uC. Precipitated proteins
were eluted with 26 SDS-PAGE sample buffer and boiled for
10 minutes. Cell lysates and immunoprecipitated proteins were
analysed by SDS-PAGE using 3–8% TrisAcetate or 4–12% Bis-Tris
NuPAGE gels (Novex). Proteins were detected using the indicated
primary antibodies and the Odyssey infrared imaging system
(Odyssey). Protein bands were quantitated by densitometry, and
analysed using GeneTools software.
Purification of APC-rich protrusions
Pseudopodia were extracted as described by [37]. To monitor
APC rich protrusions, serum starved MDCK cells (1610
5 or
1610
6) were placed in the upper compartment of a chamber (12
or 24 mm, respectively) containing a 3.0-mm porous polycarbonate
membrane insert. Cells were allowed to attach for 2 h with 2 ng/
ml HGF (R and D Systems), and then inserts placed in chambers
containing serum free DMEM or DMEM+10%FCS. Cells were
allowed to extend pseudopodia through the pores for 24 h.
Pseudopodia (PS) and cell bodies (CB) on the lower- and upper-
surface of the filter were immunostained using standard methods,
after first removing upper and lower-surface proteins, respectively,
as described [37]. Co-staining with DAPI revealed nuclei on the
upper surface (cell body) but not the undersurface (pseudopodia).
To extract proteins, 5610
5 cells were induced to extend
protrusions across the filter. Proteins on the lower-(PS) and upper-
(CB) surface of the filter were scraped directly into Lysis Buffer
after first removing upper- and lower-surface proteins, respective-
ly, by wiping the surface as described [37]. We typically obtain
20 mg of protein from pseudopodia from each 24 mm well which
represents ,5% of total cellular protein, similar to protein
amounts reported by [37].
Supporting Information
Figure S1 Reduction of phospho-b-catenin following b-catenin
siRNA treatment MDCK cells were treated with siRNA directed
against b-catenin or a control sequence. Cells were harvested for
immunoblot analysis 72 h after siRNA transfection. Shown is b-
catenin immunoblot analysis of 1%Triton, 1% Deoxycholate
extracts from control and b-catenin siRNA treated MDCK cells.
In b-catenin siRNA treated cells, b-catenin was decreased ,70%
(n=3).
Found at: doi:10.1371/journal.pone.0014127.s001 (6.53 MB TIF)
Figure S2 Phospho-b-catenin antibodies are specific. (A) P41/45
b-catenin antibody staining demonstrates cell membrane localisa-
tion in the absence but not in the presence of the competing
phospho-peptide. MDCK cells were fixed and immunostained
with P41/45-b-catenin antibodies preincubated with P41/45-b-
catenin blocking peptide. Bottom panels show mitotic cells co-
stained with DAPI showing the specific increase in cytoplasmic
phospho-b-catenin in mitotic cells. Upper panels are confocal Z
projections, lower panels are single confocal sections of immuno-
stained MDCK cells, scale bar 20 mm. (B) P33/37/41 b-catenin
antibody staining demonstrates cell membrane (arrow), centro-
some (arrowhead), intracellular cluster (dashed arrow) as well as
mid-body bridge (not shown), in the absence but not in the
presence of the competing phosphopeptide. MDCK cells were
fixed and immunostained with P33/37/41 b-catenin antibdies
preincubated with P33/37/41 b-catenin blocking peptide. Shown
are confocal Z projections of immunostained cells, scale bar
20 mm. Phospho-peptides contain the same sequence as the
antigen used to raise phospho-b-catenin antibodies.
Found at: doi:10.1371/journal.pone.0014127.s002 (3.77 MB TIF)
Figure S3 Phospho-b-catenin antibodies recognise phosphory-
lated but not unphosphorylated b-catenin. (A) Immunoblot
analysis of purified recombinant wild type b-catenin and S45A -
b-catenin phosphorylated with CK1a alone, GSK3b alone and
CK1a+GSK3b probed with b-catenin and phospho-b-catenin
antibodies, as indicated. P41/45 phospho-b-catenin antibodies
recognise b-catenin phosphorylated by CK1a alone and
CK1a+GSK3b but not GSKb alone; P33/37/41 phospho-b-
catenin antibodies recognise b-catenin phosphorylated by
CK1a+GSK3b but not CK1a or GSK3b alone. S45A b-catenin
is not phosphorylated by CK1a and is therefore not recognised by
P41/45 or P33/37/41-b-catenin antibodies. Full length mouse b-
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into pET-DUET as an Asc1/Not1 fragment, was expressed in
E.coli BL21 (DE3) cells as an N-terminal His6 fusion protein was
purified using nickel affinity and size exclusion chromatography.
Active CK1a (a kind gift from Dr Jorge Allende) was expressed in
E.coli BL21 (DE3) and part-purified as a His6 fusion protein by
Ni-affinity chromatography. GSK3b with an N-terminal Flag
epitope tag was subcloned into the baculovirus vector pBlueBac4
(Invitrogen) and recombinant protein produced in Sf9 cells. Flag-
GSK3b was purified by affinity chromatography using anti-Flag-
M2 agarose (Sigma) followed by size exclusion chromatography.
20 pmols purified recombinant His6-b-catenin or His6-b-catenin
S45A mutant was phosphorylated in the presence of 1 mM ATP,
4 mM MgCl2, 150 mM NaCl, 20 mM Tris-HCl, pH 7.5 using
recombinant His6-CK1a and Flag-GSK3b. Reactions were
performed in a final volume of 20 ml at room temperature for
30 min, terminated by the addition of SDS-PAGE loading buffer,
and separated by SDS-PAGE (4–12% Bis-Tris). Phosphate
incorporation was verified by performing the reaction in the
presence of 2 2mCi c
32P-ATP followed by phospho-imaging, or
by immunoblot with the indicated antibodies. (B) Autoradiograph
of phosphorylated b-catenin from (A) showing incorporation of
32P phosphate followingphosphorylation by CK1a and
CK1a+GSK3b but not GSK3b alone.
Found at: doi:10.1371/journal.pone.0014127.s003 (1.68 MB TIF)
Figure S4 Specificity of phospho-b-catenin antibodies (A)
LIM2551 cells, containing mutated b-catenin that results in
deletion of amino acids 5–72 [30], show little to no detectable
P41/45 b-catenin and P33/37/41 b-catenin in interphase cells.
Shown are confocal sections of LIM2551 cells immunostained
with P41/45 b-catenin (top) and P33/37/41 b-catenin (bottom)
antibodies and costained with DAPI, scale bar 20 mm. (B) P33/
37/41 b-catenin antibodies stain centrosomes and mid-body
bridges in mitotic LIM2551 cells. It is important to note that as
b-catenin does not contain the P33/37/41 b-catenin epitope, this
staining is not related to b-catenin. Shown are confocal
micrographs of LIM2551 cells immunostained with P33/37/41
b-catenin and b-tubulin antibodies and co-stained with DAPI to
visualise DNA, scale bar 5 mm.
Found at: doi:10.1371/journal.pone.0014127.s004 (1.47 MB TIF)
Figure S5 Detection of phosphorylated-b-catenin in colon
cancer cells. Immunoblots of MDCK and colon cancer cell lysates
demonstrate that the major band detected by P41/45- and P33/
37/41-b-catenin antibodies co-migrates with b-catenin. Filters
were probed with antibodies to the indicated proteins. Cells
containing mutations in APC (LIM2537 and SW480) have
detectable phospho-b-catenin. Cells containing b-catenin muta-
tions at S45 (LIM1899 and HCT116) do not have detectable P41/
45-b-catenin but are still phosphorylated at P33/37/41. LIM1215
cells contain a mutation at T41. Note that in LIM2551 cells, b-
cateninD5–72 migrates faster by SDS-PAGE consistent with the
size of the mutated protein and is not detected by P41/45 or P33/
37/41. Cells treated with 30 mM LiCl do not show any change in
P41/45-b-catenin, as expected, but show reduced P33/37/41-b-
catenin as detected by P41/45- and P33/37/41-b-catenin
antibodies, respectively. Shown are representatives of at least
three separate experiments.
Found at: doi:10.1371/journal.pone.0014127.s005 (1.98 MB
TIF)
Figure S6 Axin is localised to cytoplasmic puncta and not at cell
junctions or the ends of cell extensions in MDCK cells. MDCK
cells were serum starved and untreated (control (A and C)) or
treated with HGF (2 ng/ml) for 6 h (B and D), fixed and
immunostained with axin and b-tubulin (A and B) and axin or
APC (C and D) antibodies and co-stained with DAPI to visualise
nuclei. Left panels are grey scale images of axin; Right panels are
merged images, axin (green), b-tubulin/APC (red), nuclei (blue).
Axin was not detected at the cell periphery or at the ends of
microtubules in control or HGF stimulated cells. Scale bars
20 mm.
Found at: doi:10.1371/journal.pone.0014127.s006 (6.25 MB TIF)
Figure S7 Phosphorylated b-catenin is localised in clusters to the
ends of microtubules and is coincident with APC. MDCK cells
were immunostained with antibodies to P41/45- (A) or P33/37/
41-b-catenin (B) (green), APC (magenta) and b-tubulin (blue) and
in (B) co-stained with TO-PRO-3 iodide to visualise nuclei (cyan).
APC clusters and coincident phospho-b-catenin (white) are
indicated with green arrowheads. Note that APC decorates the
ends of microtubules; in tight colonies, the cell protrusions are not
distinct and extend across the epithelial monolayer so it is
sometimes not obvious that the APC clusters are at the ends of
microtubules even when cells are costained with tubulin (see A).
However, at the edges of colonies, the ends of microtubules are
distinct and the APC clusters at cell protrusions are clearly
visible.Shown are confocal sections, scale bar 20 mm.
Found at: doi:10.1371/journal.pone.0014127.s007 (8.56 MB TIF)
Figure S8 Inhibition of b-catenin phosphorylation in MDCK
cells. Lysates from MDCK cells treated with GSK3b and CK1a
inhibitors and immunoblotted as indicated. (A) P33/37/41-b-
catenin is reduced following treatment with all kinase inhibitors,
but most strongly following inhibition with GSK3b inhibitors,
LiCl and kenpaullone. (B) P41/45-b-catenin is reduced following
treatment with D4476, and reduced slightly with IC261, but not
by treatment with GSK3b inhibitors, LiCl and kenpaullone. C)
P41/45-b-catenin remains localised in sub-populations at cell
junctions (arrows) and in clusters coincident with APC (arrow-
heads) following treatment with GSK3b inhibitor, LiCl. Scale
10 mm.
Found at: doi:10.1371/journal.pone.0014127.s008 (3.21 MB TIF)
Figure S9 Inhibition of CK1 results in loss of phospho-b-catenin
at cell-cell contacts. MDCK cells were treated with vehicle control
or D4476 (100 mM) for 1 h, fixed and immunostained with
antibodies to P41/45 b-catenin or P33/37/41b-catenin (green),
APC or E-cadherin (red), and co-stained with DAPI to visualise
nuclei. (A) P41/45 b-catenin (green), APC (red), nuclei (blue). (B)
P41/45 b-catenin (green), E-cadherin (red), nuclei (blue). (C) P33/
37/41 b-catenin (green), APC (red), nuclei (blue). Phospho b-
catenin cell contact staining, indicated by solid arrows, is lost in
D4476 treated cells but co-incident APC staining, indicated by
dashed arrows, and cytoplasmic staining in mitotic cells (*) remains
after treatment. Shown are confocal sections, scale bars 20 mm.
Found at: doi:10.1371/journal.pone.0014127.s009 (7.60 MB TIF)
Figure S10 Inhibition of protein phosphatases results in an
increase in P33/37/41-b-catenin associated with APC. (A)
MDCK cells were pre-treated with 30 mM NaCl or LiCl for
30 min, cells were washed 26and incubated in DME+10% FCS
containing vehicle control or okadaic acid (20 nM). Cells were
harvested at T0, 5, 10 and 20 min and lysates immunoblotted with
P33/37/41-anti rabbit-IR800 and reprobed with actin-anti-
mouse-IR700 antibodies. The numbers below each lane reflect
normalised densitometry values. Shown is a representative of at
least 3 independent experiments. There is a modest increase in
phosphorylated (P33/37/41)-b-catenin in the presence of the
phosphatase inhibitor. (B) MDCK cells were pre-treated with
30 mM NaCl or LiCl for 30 min and cells were washed 26and
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Calyculin (20 nM) for 20 min. Fixed cells were immunostained
with P33/37/41-b-catenin (green) and APC (red) antibodies and
costained with DAPI. P33/37/41-b-catenin coincident with APC
clusters at cell protrusions is reduced with LiCl treament and is
partially restored after LiCl is washed out. Incubation with
phosphatase inhibitor, Calyculin, results in increased P33/37/41-
b-catenin in clusters coincident with APC. Representative fields
for each treatment are shown in left panels. Arrowheads indicate
APC clusters. Scale bar 20 mm. Cells were scored for coincident
P33/37/41-b-catenin and APC staining and plotted in right panel.
Shown is average +/2 SD from three independent experiments,
.100 cells per treatment group. **P,0.02, ***P,0.005,
****P=0.00005 by Students t test.
Found at: doi:10.1371/journal.pone.0014127.s010 (3.08 MB TIF)
Figure S11 APC is required for phospho-b-catenin localisation
to the ends of microtubules. MDCK cells transfected with control
and APC siRNA were immunostained for P33/37/41 b-catenin
(green), APC (magenta) and E-cadherin (blue) with grey scale
images shown below and enlarged in insets. Arrowheads indicate
clusters of phospho-b-catenin at cell extensions coincident with
APC in control but not APC depleted cells. White arrows indicate
intact junctional phospho-b-catenin; green arrows indicate
concentrations of phospho-b-catenin coincident with E-cadherin.
Scale bars 20 m (insets, 10 m).
Found at: doi:10.1371/journal.pone.0014127.s011 (5.37 MB TIF)
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